EDN1 and B-cell chronic lymphocytic leukemia: Altogether these findings strongly suggest an impact of ET-1 axis in CLL pathobiology and envision the possibility to explore a novel class of agents interfering with ET receptors, also in combinations with new drugs currently available or actually tested in clinical trials such as ibrutinib, idelalisib and ABT-199.